|
 |
| |
| |
| Licensing & Royalties >> Licensing Opportunities >> Abstract Details |
|
| |
| Methods for Treating or Ameliorating Fibrosis by Inhibiting the Interaction between IL-21 Receptor (IL-21R) and IL-21 |
Description of Invention:
This invention includes methods for treating or ameliorating fibrosis by inhibiting the interaction between IL-21 Receptor (IL-21R) and IL-21 using either anti-IL-21R monoclonal antibodies (or binding fragments of anti-IL-21R mAbs), anti-IL-21 monoclonal antibodies (or binding fragments of anti-IL-21 mAbs) or soluble IL-21R (or binding fragments of IL-21R). It is believed that the TH2 immune response, induced by IL-21, plays a major role in the in the pathogenesis of tissue fibrosis. Antagonism of IL-21R by anti-IL-21R monoclonal antibodies or the sequestration of IL-21 by soluble IL-21R or anti-IL-21 monoclonal antibodies has been demonstrated to reduce TH2 immune responses associated with fibrosis in animal models.
The causes of chronic tissue fibrosis are diverse and the market for a therapeutic that targets fibrosis is large. Fibrosis is associated with diverse causes which include: genetic diseases (such as cystic fibrosis); autoimmune diseases (such as scleroderma); chronic viral infections (such as hepatitis), parasitic infections (such as schistosomiasis); and occupational exposures to causative agents (such as asbestosis). Additionally, many cases of tissue fibrosis are idiopathic.
Applications:
The treatment or amelioration of tissue fibrosis.
Inventors:
Thomas A Wynn (NIAID)
Patent Status:
HHS, Reference No. E-250-2005/0
US, , Patent No. 7,910,105, Issued 22 Mar 2011
PCT, Application No. PCT/US2006/013829 filed 13 Apr 2006
International rights available.
Relevant Publication:
- J Pesce et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J Clin Invest 2006 Jul;116(7):2044-2055. [PubMed abs]
Licensing Status:
Available for licensing.
Collaborative Research Opportunity:
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this invention. Please contact Nicole Mahoney at 301-435-9017 or mahoneyn@niaid.nih.gov for more information.
For Licensing Information Please Contact:
Surekha Vathyam Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: vathyams@mail.nih.gov
Phone: 301-435-4076
Fax: 301-402-0220
Ref No: 1996
Updated: 07/2009
|
|
|
|
| |
|
|
|
|